Amyotrophic Lateral Sclerosis

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2022 Sep 18

PMID 36116464

Authors

Eva L Feldman

Stephen A Goutman

Susanne Petri

Letizia Mazzini

Masha G Savelieff

Pamela J Shaw

Gen Sobue

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive research, current management of amyotrophic lateral sclerosis remains suboptimal from diagnosis to prognosis. Recognition of the phenotypic heterogeneity of amyotrophic lateral sclerosis, global CNS dysfunction, genetic architecture, and development of novel diagnostic criteria is clarifying the spectrum of clinical presentation and facilitating diagnosis. Insights into the pathophysiology of amyotrophic lateral sclerosis, identification of disease biomarkers and modifiable risks, along with new predictive models, scales, and scoring systems, and a clinical trial pipeline of mechanism-based therapies, are changing the prognostic landscape. Although most recent advances have yet to translate into patient benefit, the idea of amyotrophic lateral sclerosis as a complex syndrome is already having tangible effects in the clinic. This Seminar will outline these insights and discuss the status of the management of amyotrophic lateral sclerosis for the general neurologist, along with future prospects that could improve care and outcomes for patients with amyotrophic lateral sclerosis.

Citing Articles

Evidence-Based Nutritional Recommendations for Maintaining or Restoring Nutritional Status in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review.

de Carvalho Vilar M, Coutinho K, de Lima Vale S, Dourado Junior M, de Medeiros G, Piuvezam G Nutrients. 2025; 17(5).

PMID: 40077653 PMC: 11901627. DOI: 10.3390/nu17050782.

Adverse events reporting of edaravone: a real-world analysis from FAERS database.

Shang Q, Zhou J, Ye J, Chen M Sci Rep. 2025; 15(1):8148.

PMID: 40059194 PMC: 11891309. DOI: 10.1038/s41598-025-92605-5.

Endogenous TDP-43 mislocalization in a novel knock-in mouse model reveals DNA repair impairment, inflammation, and neuronal senescence.

Mitra J, Kodavati M, Dharmalingam P, Guerrero E, Rao K, Garruto R Acta Neuropathol Commun. 2025; 13(1):54.

PMID: 40057796 PMC: 11889789. DOI: 10.1186/s40478-025-01962-9.

Increased risk of ischemic stroke in amyotrophic lateral sclerosis: a nationwide cohort study in South Korea.

Kwon S, Kim B, Han K, Jung W, Cho E, Shin D Neurol Sci. 2025; .

PMID: 40048117 DOI: 10.1007/s10072-025-08074-1.

Role of iron in brain development, aging, and neurodegenerative diseases.

Gao Q, Zhou Y, Chen Y, Hu W, Jin W, Zhou C Ann Med. 2025; 57(1):2472871.

PMID: 40038870 PMC: 11884104. DOI: 10.1080/07853890.2025.2472871.

References

Miller R, Brooks B, Swain-Eng R, Basner R, Carter G, Casey P . Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013; 81(24):2136-40. PMC: 3863352. DOI: 10.1212/01.wnl.0000437305.37850.f9. View

Beeldman E, Govaarts R, de Visser M, Klein Twennaar M, van der Kooi A, van den Berg L . Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91(7):779-780. PMC: 7361007. DOI: 10.1136/jnnp-2020-322992. View

Mullard A . ALS antisense drug falters in phase III. Nat Rev Drug Discov. 2021; 20(12):883-885. DOI: 10.1038/d41573-021-00181-w. View

Goutman S, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman E . High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019; 90(8):907-912. PMC: 6625908. DOI: 10.1136/jnnp-2018-319785. View

Freibaum B, Lu Y, Lopez-Gonzalez R, Kim N, Almeida S, Lee K . GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015; 525(7567):129-33. PMC: 4631399. DOI: 10.1038/nature14974. View

Alshikho M, Zurcher N, Loggia M, Cernasov P, Reynolds B, Pijanowski O . Integrated magnetic resonance imaging and [ C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018; 83(6):1186-1197. PMC: 6105567. DOI: 10.1002/ana.25251. View

Shayya L, Babu S, Pioro E, Li J, Li Y . Distal Predominance of Electrodiagnostic Abnormalities in Early-Stage Amyotrophic Lateral Sclerosis. Muscle Nerve. 2018; 58(3):389-395. DOI: 10.1002/mus.26158. View

Li C, Ou R, Wei Q, Shang H . Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol Aging. 2021; 102:211.e1-211.e9. DOI: 10.1016/j.neurobiolaging.2021.01.023. View

Fang T, Al Khleifat A, Meurgey J, Jones A, Leigh P, Bensimon G . Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018; 17(5):416-422. PMC: 5899963. DOI: 10.1016/S1474-4422(18)30054-1. View

10.

Walhout R, Verstraete E, van den Heuvel M, Veldink J, van den Berg L . Patterns of symptom development in patients with motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 19(1-2):21-28. DOI: 10.1080/21678421.2017.1386688. View

11.

Al-Chalabi A, Hardiman O . The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013; 9(11):617-28. DOI: 10.1038/nrneurol.2013.203. View

12.

Morata-Tarifa C, Azkona G, Glass J, Mazzini L, Sanchez-Pernaute R . Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. NPJ Regen Med. 2021; 6(1):20. PMC: 8016966. DOI: 10.1038/s41536-021-00131-5. View

13.

Ringholz G, Appel S, Bradshaw M, Cooke N, Mosnik D, Schulz P . Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005; 65(4):586-90. DOI: 10.1212/01.wnl.0000172911.39167.b6. View

14.

Shefner J, Heiman-Patterson T, Pioro E, Wiedau-Pazos M, Liu S, Zhang J . Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve. 2019; 61(2):218-221. PMC: 7004197. DOI: 10.1002/mus.26740. View

15.

Goutman S, Hardiman O, Al-Chalabi A, Chio A, Savelieff M, Kiernan M . Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022; 21(5):465-479. PMC: 9513754. DOI: 10.1016/S1474-4422(21)00414-2. View

16.

Dhulst L, Van Weehaeghe D, Chio A, Calvo A, Moglia C, Canosa A . Multicenter validation of [F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19(7-8):570-577. DOI: 10.1080/21678421.2018.1476548. View

17.

Camu W, Mickunas M, Veyrune J, Payan C, Garlanda C, Locati M . Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2020; 59:102844. PMC: 7502670. DOI: 10.1016/j.ebiom.2020.102844. View

18.

Amado D, Davidson B . Gene therapy for ALS: A review. Mol Ther. 2021; 29(12):3345-3358. PMC: 8636154. DOI: 10.1016/j.ymthe.2021.04.008. View

19.

Menon P, Yiannikas C, Kiernan M, Vucic S . Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2019; 6(8):1373-1382. PMC: 6689694. DOI: 10.1002/acn3.50819. View

20.

Rascovsky K, Hodges J, Knopman D, Mendez M, Kramer J, Neuhaus J . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(Pt 9):2456-77. PMC: 3170532. DOI: 10.1093/brain/awr179. View